Literature DB >> 21188423

Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Valérie Leroy1, Véronique Fremeaux-Bacchi, Michel Peuchmaur, Véronique Baudouin, Georges Deschênes, Marie-Alice Macher, Chantal Loirat.   

Abstract

The development of membranoproliferative glomerulonephritis (MPGN) is associated with uncontrolled activation of the complement alternative pathway. This dysregulation is related either to C3 nephritic factor (C3NeF), an auto-antibody directed against the alternative C3 convertase, or to homozygous loss-of-function mutation of the complement regulatory protein factor H. Heterozygous mutations in the genes coding for factor H, or for the other alternative pathway inhibitory proteins factor I and membrane cofactor protein, have recently been identified in a small number of patients with MPGN with exclusive C3 deposits. We report three hypocomplementemic children with dense deposit disease (n=1) or immune-complex-mediated MPGN type I (n=2), associated with both C3NeF activity and heterozygous mutation of factor H or factor I. These observations highlight the possible combination of genetic and acquired defect in complement control in various subtypes of MPGN, a finding that may influence the treatment strategy in some patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188423     DOI: 10.1007/s00467-010-1734-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  23 in total

1.  C3 deposition glomerulopathy due to a functional factor H defect.

Authors:  Sandra Habbig; Michael J Mihatsch; Stefan Heinen; Bodo Beck; Mathias Emmel; Christine Skerka; Michael Kirschfink; Bernd Hoppe; Peter F Zipfel; Christoph Licht
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

2.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

3.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

4.  Changing patterns in the histopathology of idiopathic nephrotic syndrome in children.

Authors:  M Bonilla-Felix; C Parra; T Dajani; M Ferris; R D Swinford; R J Portman; R Verani
Journal:  Kidney Int       Date:  1999-05       Impact factor: 10.612

5.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

6.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Authors:  Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

7.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

8.  Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; S Watanabe; T Fujita; T Yasugi
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

9.  Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.

Authors:  F Vaziri-Sani; L Holmberg; A G Sjöholm; A-C Kristoffersson; M Manea; V Frémeaux-Bacchi; I Fehrman-Ekholm; R Raafat; D Karpman
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

10.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

Authors:  K Høgåsen; J H Jansen; T E Mollnes; J Hovdenes; M Harboe
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  17 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  C3 nephritic factor can be associated with membranous glomerulonephritis.

Authors:  Olivier Niel; Aymeric Dallocchio; Marie-Christine Thouret; Vincent Guigonis; Élisabeth Cassuto; Véronique Frémeaux-Bacchi; Étienne Bérard
Journal:  Pediatr Nephrol       Date:  2014-11-14       Impact factor: 3.714

3.  Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.

Authors:  Khalid Alfakeeh; Mohammed Azar; Majid Alfadhel; Alsuayri Mansour Abdullah; Nourah Aloudah; Khaled O Alsaad
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

Review 4.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

5.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

Review 6.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

Review 7.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

8.  Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis.

Authors:  Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Am J Kidney Dis       Date:  2012-04-26       Impact factor: 8.860

9.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

10.  C3 nephritic factor associated with C3 glomerulopathy in children.

Authors:  Camille Nicolas; Vincent Vuiblet; Veronique Baudouin; Marie-Alice Macher; Isabele Vrillon; Nathalie Biebuyck-Gouge; Maud Dehennault; Sophie Gié; Denis Morin; Hubert Nivet; François Nobili; Tim Ulinski; Bruno Ranchin; Maria Chiarra Marinozzi; Stéphanie Ngo; Véronique Frémeaux-Bacchi; Christine Pietrement
Journal:  Pediatr Nephrol       Date:  2013-09-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.